文献速递胸部肿瘤

抗生素对非小细胞肺癌免疫检查点抑制剂疗效的影响因PD-L1表达而异

The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
PubMed 文献 · Eur J Cancer · 2021-04-07

该回顾性多中心研究纳入531例接受ICI单药治疗的NSCLC患者,发现抗生素使用与更短中位OS相关(11.7 vs 16.1个月,p=0.028),PFS无显著差异。在PD-L1≥50%患者中,抗生素使用显著缩短PFS和OS;而PD-L1<50%患者中无显著差异。

要点

  • 抗生素使用与NSCLC患者ICI治疗后更短OS相关,PFS无显著差异。
  • PD-L1≥50%患者中,抗生素使用显著缩短PFS和OS。
  • PD-L1<50%患者中,抗生素使用对PFS和OS无显著影响。

核心结论

  • 抗生素使用对晚期NSCLC患者ICI疗效的影响因PD-L1表达水平而异,PD-L1≥50%患者中负面影响显著,PD-L1<50%患者中未观察到显著影响。

研究设计与样本

  • 回顾性多中心研究,纳入2015年12月至2018年5月在九家机构接受ICI单药治疗的531例NSCLC患者。

主要发现

  • 抗生素使用与更短中位OS显著相关(11.7 vs 16.1个月,p=0.028),PFS无显著差异(3.5 vs 3.5个月,p=0.287)。
  • PD-L1<50%患者中,抗生素组与非抗生素组PFS(3.3 vs 2.8个月,p=0.88)和OS(9.5 vs 17.1个月,p=0.24)无显著差异。
  • PD-L1≥50%患者中,抗生素组PFS(4.2 vs 9.4个月,p=0.012)和OS(11.9 vs 28.4个月,p=0.011)显著缩短。

临床怎么用

  • 对于PD-L1≥50%的NSCLC患者,接受ICI治疗时应谨慎使用抗生素,以避免潜在疗效降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) are essential for treatment of various malignancies, including non-small-cell lung cancer (NSCLC). Recently, several studies have shown that the gut microbiome plays an important role in ICI treatment of solid cancers, and antibiotic (ATB) use had a negative impact on the outcomes of ICI treatment via dysbiosis in the gut. However, whether this is applicable to NSCLC remains unclear. The impact of ATBs based on PD-L1 expression also remains unclear. METHODS: We retrospectively reviewed the medical records of patients with NSCLC who received ICI monotherapy (anti-PD-1 or anti-PD-L1 antibody) at nine institutions from December 2015 to May 2018. Outcomes with use of ATBs during the 2 months before or a month after initiation of ICI treatment, including progression-free survival (PFS) and overall survival (OS), were investigated using the Kaplan-Meier method. Multivariate analysis was also conducted using a Cox proportional hazards model. RESULTS: A total of 531 patients were included in this study, among whom 98 (18.5%) received ATBs before or after ICI treatment. ATB use was significantly associated with a shorter median OS (11.7 months in the ATB group vs. 16.1 months in the non-ATB group; p = 0.028), whereas the difference in PFS was not significant (3.5 months in both the groups; p = 0.287). We next investigated the association based on PD-L1 expression in the 265 patients for whom PD-L1 expression was determined. There was no significant difference in the median OS or PFS between patients with NSCLC and PD-L1 expression <50% receiving ATBs and those not receiving ATBs (PFS: 3.3 vs. 2.8 months, p = 0.88; OS: 9.5 vs. 17.1 months, p = 0.24). Conversely, patients with NSCLC and PD-L1 expression ≥50% receiving ATBs showed significantly shorter median PFS and OS (PFS: 4.2 vs. 9.4 months, p = 0.012; OS: 11.9 vs. 28.4 months, p = 0.011). The impact of ATBs in patients with NSCLC and PD-L1 expression ≥50% was more significant than that in the entire cohort. CONCLUSIONS: Our results indicate that the impact of ATB use on the efficacy of ICIs differed based on PD-L1 expression in patients with advanced NSCLC. A negative impact of ATB use was found in patients with NSCLC and PD-L1 expression ≥50% but not in those with PD-L1 expression <50%.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ochi N, Ichihara E, Takigawa N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021. PMID: 33838391. doi:10.1016/j.ejca.2021.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。